





## VON GRAFFENRIED TREUHAND

### Report of the statutory auditors to the Foundation Board of Fairmed Foundation, Berne

#### Report on the Audit of the Financial Statements

##### *Opinion*

We have audited the financial statements of Fairmed Foundation, which comprise the balance sheet as at 31. December 2022 and the operating accounts and the statement of cash flows and the statement of change in capital for the year then ended, and notes to the financial statement, including a summary of significant accounting policies. In accordance with Swiss GAAP FER 21 the information in the performance report is not subject to audit or examination work performed by the statutory auditor.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of the Foundation as at 31 December 2022 and of its financial performance and its cash flows for the year then ended in accordance with Swiss GAAP FER and comply with Swiss law, with statutes and with regulation.

##### *Basis for Opinion*

We conducted our audit in accordance with Swiss law and Swiss Standards on Auditing (SA-CH). Our responsibilities under those provisions and standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our report. We are independent of the Foundation in accordance with the provisions of Swiss law and the requirements of the Swiss audit profession, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

##### *Other points*

The financial statements for the year ended 31 December 2021 have been audited by another auditor, which expressed in its report dated 8 April 2022 an unmodified opinion on these financial statements.

##### *Foundation Board's Responsibilities for the Financial Statements*

The Foundation Board is responsible for the preparation of the financial statements, which give a true and fair view in accordance with Swiss GAAP FER and the provisions of Swiss law, and for such internal control as the Foundation Board determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Foundation Board is responsible for assessing the Foundation's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Foundation Board either intends to liquidate the Foundation or to cease operations, or has no realistic alternative but to do so.

##### *Auditor's Responsibilities for the Audit of the Consolidated Financial Statements*

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Swiss law and SA-CH will always detect a material misstatement when it



## VON GRAFFENRIED TREUHAND

exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on EXPERT-suisse's website at: <https://www.expertsuisse.ch/en/audit-report>. This description forms an integral part of our report.

### Report on Other Legal and Regulatory Requirements

In accordance with Art. 728a para. 1 item 3 CO and PS-CH 890, we confirm that an internal control system exists, which has been designed for the preparation of the financial statements according to the instructions of the Board of Directors.

We recommend that the consolidated financial statements (balance sheet with a total of CHF 3'579'892, income statement with an operating result of CHF -140'755'011, cash flow statement, statement of change in capital and notes) submitted to you be approved.

Berne, 27 April 2023 ris/stn

Von Graffenried AG Treuhand

Michel Zumwald  
Swiss Certified Accountant  
Licensed audit expert

Stephan Richard  
Swiss Certified Accountant  
Licensed audit expert  
Auditor in charge

**Von Graffenried AG Treuhand**

Waaghausgasse 1, Postfach, CH-3001 Bern, Tel. +41 31 320 56 11, Fax +41 31 320 56 90



# Balance Sheet

as at 31 Dezember 2022

(in CHF)

## Assets

|                                       | 31.12.2022       | %            | 31.12.2021       | %            |
|---------------------------------------|------------------|--------------|------------------|--------------|
| Cash                                  | 4'165            |              | 4'159            |              |
| Postfinance                           | 826'962          |              | 1'316'381        |              |
| Banks                                 | 948'894          |              | 535'366          |              |
| <b>Cash equivalents</b>               | <b>1'780'021</b> | <b>49.7</b>  | <b>1'855'906</b> | <b>46.5</b>  |
| Accounts receivable                   |                  |              |                  |              |
| • Other current accounts receivable   | 189'122          |              | 160'632          |              |
| Accrued income (AI)                   | 18'768           |              | 43'221           |              |
| <b>Accounts receivable and AD</b>     | <b>207'890</b>   | <b>5.8</b>   | <b>203'853</b>   | <b>5.1</b>   |
| <b>Current assets</b>                 | <b>1'987'912</b> | <b>55.5</b>  | <b>2'059'759</b> | <b>51.6</b>  |
| <b>Tangible assets</b>                | <b>1'603</b>     | <b>0.0</b>   | <b>3'053</b>     | <b>0.1</b>   |
| <b>Financial assets <sup>1)</sup></b> | <b>1'590'377</b> | <b>44.4</b>  | <b>1'930'763</b> | <b>48.3</b>  |
| <b>Fixed assets</b>                   | <b>1'591'980</b> | <b>44.5</b>  | <b>1'933'816</b> | <b>48.4</b>  |
| <b>Total assets</b>                   | <b>3'579'892</b> | <b>100.0</b> | <b>3'993'575</b> | <b>100.0</b> |

## Liabilities

|  |                  |              |                  |              |
|--|------------------|--------------|------------------|--------------|
| Liabilities                                    |                  |              |                  |              |
| • Trade payables                               | 288'445          |              | 202'982          |              |
| • «Leprahilfe» linked account, affiliate       | 20'034           |              | 20'034           |              |
| Other short-term liabilities                   | 1'968            |              | 18'044           |              |
| Passive accruals and deferrals (AD)            | 38'800           |              | 40'755           |              |
| <b>Short-term liabilities and AD</b>           | <b>349'247</b>   | <b>9.8</b>   | <b>281'816</b>   | <b>7.1</b>   |
| Designated funds                               |                  |              |                  |              |
| • Prevention / control leprosy Sri Lanka       | 0                |              | 17'515           |              |
| • Funds from the Gertrud von Haller Foundation | 0                |              | 65'334           |              |
| • Basic healthcare Bobélé CAR                  | 0                |              | 6'253            |              |
| • Basic healthcare CAR                         | 0                |              | 37'831           |              |
| <b>Fund capital</b>                            | <b>0</b>         | <b>0.0</b>   | <b>126'933</b>   | <b>3.2</b>   |
| <b>Debt and fund capital</b>                   | <b>349'247</b>   | <b>9.8</b>   | <b>408'749</b>   | <b>10.2</b>  |
| Foundation capital                             | 500'000          |              | 500'000          |              |
| Corporate funds (free capital)                 | 2'412'645        |              | 2'698'826        |              |
| Value fluctuation fund                         | 318'000          |              | 386'000          |              |
| <b>Organisational capital</b>                  | <b>3'230'645</b> | <b>90.2</b>  | <b>3'584'826</b> | <b>89.8</b>  |
| <b>Total liabilities</b>                       | <b>3'579'892</b> | <b>100.0</b> | <b>3'993'575</b> | <b>100.0</b> |

# Operating Statement

| (in CHF)  | 2022              | %            | 2021              | %            |
|---|-------------------|--------------|-------------------|--------------|
| Contributions received and other income                       |                   |              |                   |              |
| Donations   | 3'446'169         |              | 3'762'415         |              |
| Dedicated project contributions <sup>2)</sup>                 |                   |              |                   |              |
| • General   | 3'542'624         |              | 2'201'865         |              |
| • Cantons and municipalities                                  | 404'896           |              | 296'500           |              |
| • Leprosy Aid Emmaus Switzerland                              | 200'000           |              | 0                 |              |
| • SDC programme contributions (contract no. 81067470)         | 3'150'000         |              | 3'150'000         |              |
| Legacies and inheritances / bequeathals                       | 1'038'014         |              | 359'339           |              |
| Consultations and other income                                | 20'604            |              | 37'135            |              |
| <b>Operating income</b>                                       | <b>11'802'306</b> | <b>100.0</b> | <b>9'807'255</b>  | <b>100.0</b> |
| Expenditure on projects                                       |                   |              |                   |              |
| Project expenditure <sup>3)</sup>                             | 8'713'879         |              | 6'828'296         |              |
| Project support expenditure <sup>4)</sup>                     | 730'632           |              | 833'489           |              |
| Fundraising and general advertising expenditure <sup>5)</sup> | 1'431'167         |              | 1'385'574         |              |
| Administrative expenditure <sup>6)</sup>                      | 1'067'384         |              | 1'086'261         |              |
| <b>Operating expenditure</b>                                  | <b>11'943'061</b> | <b>101.2</b> | <b>10'133'621</b> | <b>103.3</b> |
| <b>Operating result</b>                                       | <b>-140'755</b>   | <b>-1.2</b>  | <b>-326'367</b>   | <b>-3.3</b>  |
| Financial income  | 101'702           |              | 269'667           |              |
| Financial expense   | -442'060          |              | -105'865          |              |
| <b>Financial result</b>                                       | <b>-340'358</b>   | <b>-2.9</b>  | <b>163'802</b>    | <b>1.7</b>   |
| <b>Result before change in funds</b>                          | <b>-481'113</b>   | <b>-4.1</b>  | <b>-162'565</b>   | <b>-1.7</b>  |
| Use / Withdrawal funds  | 584'733           |              | 2'046'851         |              |
| Allocation / deposit funds                                    | -457'800          |              | -1'408'795        |              |
| <b>Fund results</b>   | <b>126'933</b>    | <b>1.1</b>   | <b>638'057</b>    | <b>6.5</b>   |
| <b>Annual result before allocation organisational capital</b> | <b>-354'181</b>   | <b>-3.0</b>  | <b>475'491</b>    | <b>4.8</b>   |
| Adjustment of value fluctuation fund                          | 68'000            |              | -218'000          |              |
| Allocation (-) / withdrawal (+) to / from corporate funds     | 286'181           |              | -257'491          |              |
| <b>Total allocations (-) / withdrawals (+) funds</b>          | <b>354'181</b>    | <b>3.0</b>   | <b>-475'491</b>   | <b>-4.8</b>  |
|   | <b>0</b>          | <b>0.0</b>   | <b>0</b>          | <b>0.0</b>   |

# Cash flow statement

(in CHF)

Annual result to the benefit of corporate funds (free capital)  
 Depreciation of tangible assets  
 Price gains (–) / losses (+) on unrealised securities  
 Adjustment of value fluctuation fund  
 Fund results (+) = formation / (–) dissolution

**2022**

**2021**

–286'181  
 1'450  
 343'905  
 –68'000  
 –126'933

257'491  
 3'050  
 –95'923  
 218'000  
 –638'057

## Cash flow

**–135'759**

**–255'439**

Change in accounts receivable and AD  
 Change in short-term liabilities and AD  
 (–) = decrease / (+) = increase

–4'038

149'842

67'431

–197'479

## Cash flow from operating activity

**–72'365**

**–303'075**

Financial assets (–) = investments / (+) = divestments

–3'519

–153'332

## Cash flow from investing activity

**–3'519**

**–153'332**

## Change in liquid assets

**–75'884**

**–456'407**

## Verification of change in liquid assets

Balance 31.12.

1'780'021

1'855'906

Balance 01.01.

1'855'906

2'312'313

## Change in liquid assets

**–75'884**

**–456'407**

# Account of Fund Holdings

(change in capital)

|  | 01.01.2022       |                         |                       | 31.12.2022                |                  |
|--|------------------|-------------------------|-----------------------|---------------------------|------------------|
| (in CHF)                                   | Opening balance  | Allocations<br>External | Transfers<br>Internal | Appropriation<br>External | Ending<br>Amount |
| <b>Funds from fund capital</b>             |                  |                         |                       |                           |                  |
| Prevention / control leprosy Sri Lanka (a) | 17'515           | 74'300                  | 0                     | -91'815                   | 0                |
| Funds from Gertrud von Haller Foundation   | 65'334           | 0                       | 0                     | -65'334                   | 0                |
| Basic healthcare Bobélé CAR (b)            | 6'253            | 150'000                 | 0                     | -156'253                  | 0                |
| Basic healthcare CAR (c)                   | 37'831           | 233'500                 | 0                     | -271'331                  | 0                |
| SDC programme contribution                 | 0                | 3'150'000               | 0                     | -3'150'000                | 0                |
| Various projects                           | 0                | 3'689'720               | 0                     | -3'689'720                | 0                |
| <b>Fund capital</b>                        | <b>126'933</b>   | <b>7'297'520</b>        | <b>0</b>              | <b>-7'424'453</b>         | <b>0</b>         |
| <b>Funds from self-financing</b>           |                  |                         |                       |                           |                  |
| Foundation capital                         | 500'000          | 0                       | 0                     | 0                         | 500'000          |
| Corporate funds (free capital)             | 2'698'826        | 0                       | -286'181              | 0                         | 2'412'645        |
| Value fluctuation fund                     | 386'000          | 0                       | -68'000               | 0                         | 318'000          |
| Annual result                              | 0                | -354'181                | 354'181               | 0                         | 0                |
| <b>Organisational capital</b>              | <b>3'584'826</b> | <b>-354'181</b>         | <b>0</b>              | <b>0</b>                  | <b>3'230'645</b> |

As an institutional partner of the SDC, FAIRMED together with the Christoffel Mission for the Blind receives contributions within the scope of an international programme. The programme contribution to the benefit of FAIRMED (SDC contract no. 81067470) amounted to CHF 3'150'000 in the year under review and was used in full for projects in accordance with the programme budget.

|  | 01.01.2021       |                         |                       | 31.12.2021                |                  |
|--|------------------|-------------------------|-----------------------|---------------------------|------------------|
| (in CHF)                                 | Opening balance  | Allocations<br>External | Transfers<br>Internal | Appropriation<br>External | Ending<br>Amount |
| <b>Funds from fund capital</b>           |                  |                         |                       |                           |                  |
| Nepal RHIP Baglung                       | 270'457          | 0                       | 0                     | -270'457                  | 0                |
| Baka                                     | 1'666            | 100                     | 0                     | -1'766                    | 0                |
| EHP Nepal                                | 55'912           | 421'870                 | 0                     | -477'782                  | 0                |
| Funds DLPC phase II Sri Lanka (a)        | 27'972           | 55'000                  | 0                     | -65'457                   | 17'515           |
| Funds from Gertrud von Haller Foundation | 120'000          | 25'334                  | -80'000               | 0                         | 65'334           |
| Funds Santé Primaire Lobaye CAR          | 20'562           | 528'991                 | 80'000                | -629'553                  | 0                |
| Funds Bobélé CAR (b)                     | 268'421          | 68'000                  | 0                     | -330'168                  | 6'253            |
| Funds Sangha Mbaere CAR (c)              | 0                | 309'500                 | 0                     | -271'669                  | 37'831           |
| <b>Fund capital</b>                      | <b>764'990</b>   | <b>1'408'795</b>        | <b>0</b>              | <b>-2'046'852</b>         | <b>126'933</b>   |
| <b>Funds from self-financing</b>         |                  |                         |                       |                           |                  |
| Foundation capital                       | 500'000          | 0                       | 0                     | 0                         | 500'000          |
| Corporate funds (free capital)           | 2'441'335        | 0                       | 257'491               | 0                         | 2'698'826        |
| Value fluctuation fund                   | 168'000          | 0                       | 218'000               | 0                         | 386'000          |
| Annual result                            | 0                | 475'491                 | -475'491              | 0                         | 0                |
| <b>Organisational capital</b>            | <b>3'109'335</b> | <b>475'491</b>          | <b>0</b>              | <b>0</b>                  | <b>3'584'826</b> |

The projects were renamed in 2022. References (a) to (c) have been added for transparency and traceability.

# Appendix to the annual financial statement

## General accounting principles

The accounting is based on the principles of Swiss GAAP FER incl. FER 21 and conveys a picture of the asset position, financial and earnings situation that corresponds to the actual circumstances. The operating statement is presented according to the cost of sales accounting method, i.e. according to functional areas. The differentiation between project and administrative expenditure is based on the ZEWO method. The annual financial statement complies with Swiss accounting legislation (Articles 957 to 962 of the Swiss Code of Obligations).

## Affiliated organisations

The association «Leprosy Aid Emmaus Switzerland» regularly reimburses dedicated contributions. These are shown separately in the operating statement. Furthermore, the association makes a contribution to the administrative costs. In 2022, this amounted to CHF 26'000 (previous year CHF 3'000).

## Accounting and valuation principles

Unless otherwise indicated for the individual balance sheet items listed below, the balance sheet item is valued at market value on the balance sheet date, whereby any accrued interest is not considered a part of the market value. The accounts are kept in Swiss francs. Assets and liabilities in foreign currency are converted at the closing exchange rates on the accounting date; as far as possible, transactions in foreign currencies are converted at the current rate.

## Cash equivalents

The item includes cash and cash accounts at Postfinance and banks in Switzerland and abroad, as well as any short-term securities that are otherwise shown under financial investments.

## Accounts receivable

Valuation is at nominal value less any individual value adjustments. Project contributions are only recognised for if the commitment has been formally made. Moreover, any credit balance owed to Leprosy Aid Emmaus Switzerland is shown under this item.

## Active accruals and deferrals

The item includes the asset items that result from the functional and time definitions of the individual expenditure and income items. Valuation is at nominal value.

## Tangible assets

The item includes movable assets and other equipment such as IT hardware and software for the provision of services and administration in Switzerland. Movable assets are valued at acquisition cost less scheduled depreciation, whereby a useful life of four years is generally assumed. Depreciation is calculated using the degressive method from book value. Individual purchases under CHF 5'000 are not capitalised. Depreciation of assets is to a residual franc (pro memoria).

## Financial assets

In the course of the year, securities are registered at their purchase value; on the balance sheet date at market value (without accrued interest). In the case of reductions, the exchange rate differences from the purchase or market value of the subsequent valuation are shown in the financial result. To cover extraordinary risks of loss, a value fluctuation fund of 10% to 20% of market value is shown under organisational capital.

## Liabilities

As of the balance sheet date, this item includes project contributions that are already approved but are not yet paid out or not yet claimed by the beneficiaries. Also shown under this item are other liabilities for operating costs and, in the event of a deficit, the liaison account for Leprahilfe Emmaus Schweiz. Valuation is at nominal value.

## Passive accruals and deferrals

The item includes the liability items that result from the functional and time definitions of the individual expenditure and income items. Valuation is at nominal value.

## Fund capital

This item includes funds from contributions with a clearly defined purpose. Until the corresponding use in full, this capital represents a benefit obligation towards the donors/funders. If necessary and by agreement, the fund holding will be reduced by an administration fee. The «Gertrud von Haller Foundation for Third World Aid» funds were used in full in accordance with the agreement regarding donations to FAIRMED and in relation to the dissolution of the foundation in 2022.

## Organisational capital

The items include funds that can be employed within the framework of the statutory purpose of the Fairmed Foundation. Unused surplus from operating activity is shown in the corporate funds. The value fluctuation fund amounts to 10% to 20% of the market value of the financial assets.

## Principles of the cash flow statement

The cash flow statement shows the change in liquidity divided according to the factors of operating activity, investment activity and financing activity. The cash flow statement is prepared using the indirect method.

## Principles for the statement of changes in capital (fund holdings)

The statement of changes in capital shows the development of each dedicated fund and each individual component of the free available capital.



## Remarks on individual items in the balance sheet

### <sup>1)</sup> Financial assets

The composition of the securities is as follows:

|                                 | 2022             | 2021             |
|---------------------------------|------------------|------------------|
| Bond funds / money market funds | 225'646          | 256'774          |
| Shares / Share funds            | 1'107'926        | 1'369'187        |
| Strategy funds                  | 256'805          | 304'802          |
|                                 | <b>1'590'377</b> | <b>1'930'763</b> |

## Remarks on individual items in the operating statement

### <sup>2)</sup> Dedicated project contributions

These are project-related contributions and donations. If their purpose is more narrowly defined than the general purpose of the FAIRMED Foundation, and if the donations are significant and are not used again in the current operating year, they are allocated to a proceeds fund. If need be, project contributions can also include donations in kind (see non-monetary donations).

### <sup>3)</sup> Project expenditure

These are direct contributions towards the objectives of FAIRMED (by region):

|   | 2022             | 2021             |
|---|------------------|------------------|
| India   | 527'844          | 525'094          |
| Nepal   | 1'563'098        | 1'155'237        |
| Sri Lanka   | 250'848          | 152'964          |
| Cameroon  | 2'096'370        | 1'921'219        |
| Central African Republic                                | 2'539'160        | 2'143'217        |
| Republic of the Congo                                   | 1'063'974        | 294'543          |
| Chad  | 0                | 1'087            |
| Various projects worldwide (incl. external information) | 672'584          | 634'937          |
|   | <b>8'713'879</b> | <b>6'828'296</b> |

### <sup>4)</sup> Project support expenditure

This is expenditure in connection with the identification, planning, preparation and monitoring of projects:

|                                       | 2022             | 2021             |
|---------------------------------------|------------------|------------------|
| India                                 | 1'279            | 229              |
| Cameroon                              | 475              | 10'136           |
| Various countries and regions         | 2'383            | 14'701           |
| Personnel expenditure for projects    | 651'408          | 757'761          |
| Other accompanying costs              | 75'087           | 50'663           |
|                                       | <b>730'632</b>   | <b>833'489</b>   |
| <b>Total expenditure for projects</b> | <b>9'444'510</b> | <b>7'661'786</b> |

### <sup>5)</sup> Fundraising and general advertising expenditure

|   | 2022             | 2021             |
|---|------------------|------------------|
| Personnel expenditure   | 367'282          | 380'340          |
| Administrative expenditure (premises expenditure, repairs / upkeep / maintenance, administration costs) | 7'681            | 17'546           |
| Advertising materials for fundraising   | 226              | 155'094          |
| Postage costs for fundraising   | 190'268          | 112'161          |
| Other advertising costs for fundraising   | 813'582          | 656'979          |
| Other expenditure – PR  | 52'127           | 63'454           |
|   | <b>1'431'167</b> | <b>1'385'574</b> |

### <sup>6)</sup> Administrative expenditure

|   | 2022             | 2021             |
|---|------------------|------------------|
| Personnel expenditure                             | 722'838          | 765'046          |
| Administrative expenditure (rent and gen. admin.) | 343'096          | 318'165          |
| Depreciations                                     | 1'450            | 3'050            |
|   | <b>1'067'384</b> | <b>1'086'261</b> |

### Differentiation of administrative expenditure and fundraising

Administrative expenditure is always shown when the activity can make only an indirect contribution to the attainment of goals or to project expenditure. This applies almost exclusively to basic operational functions such as financial administration, human resources and administration. Expenditure for fundraising activities are assigned to fundraising and general advertising expenditure. In exceptional cases, awareness-raising activities that are associated with an appeal for donations can, to a limited extent, be allocated to project expenditure. The differentiation is based on the ZEWO method.

### Nature and scope of non-monetary contributions

If need be, donations in kind in the form of medicines are also included in the item Dedicated project contributions – general. There were no such donations in kind in the year under review (also no donations in the previous year).

### Information on the compensation of the Board of Trustees and remuneration of the Executive Board

As fees for specific legal services (incl. VAT), CHF 1'851 was paid to the Honorary Foundation Board in the year under review, and in the previous year CHF 3'652. The total amount of remuneration for the 4 persons (previous year 4) of the Executive Board was CHF 390'822 (previous year CHF 433'304). As at 01.10.2022, the workload amounted to 380 full-time equivalents (previous year 370 full-time equivalents).

### Post-employment benefits

The employees of FAIRMED are insured for occupational benefits through the Swiss Life Collective BVG Foundation. At the end of the year, there was no liability to the pension fund (as in the previous year). All investment and insurance risks are covered to 100 percent by Swiss Life. A shortfall in cover is not possible.

### Performance report / Management report

The Annual Report published at [www.fairmed.ch](http://www.fairmed.ch) provides detailed information on the achieved projects and goals as well as the future challenges of FAIRMED.

### Events after the balance sheet date

As a consequence of the COVID-19 pandemic and the war in Ukraine, the general economic risks have increased significantly, which also has the potential to have an impact on the activities of FAIRMED. At this point, it is not possible to estimate the specific financial impact for the current financial year.

### Information pursuant to accounting law, insofar as not already included in Swiss GAAP FER:

#### Information according to Art. 959c. OR

The yearly average of full-time employees over the year is 16 people (previous year: 15 people).

Otherwise, there are no circumstances that require disclosure.

#### Information according to Art. 961a Para. 2 OR / honorariums of the auditors

|  | 2022   | 2021   |
|--|--------|--------|
| Auditing (incl. VAT) for FAIRMED and Leprosy Relief:       | 16'800 | 16'200 |
| Other services (incl. VAT) for FAIRMED and Leprosy Relief: | 5'433  | 6'985  |

#### Management Report according to Art. OR 961c – risk assessment

FAIRMED has carried out a risk assessment as part of the annual strategy review. Recognised risks are reduced or controlled by corresponding measures adopted by the Honorary Foundation Board and the Executive Board and, if possible, avoided in the future.

## Summary of fixed assets

| (in CHF)                | 01.01.22         | Accruals | Divestiture     | Depreciations | %  | 31.12.22         |
|-------------------------|------------------|----------|-----------------|---------------|----|------------------|
| Operating equipment     | 551              | 0        | 0               | -250          | 45 | 301              |
| IT, technical equipment | 2'502            | 0        | 0               | -1'200        | 48 | 1'302            |
| <b>Tangible assets</b>  | <b>3'053</b>     | <b>0</b> | <b>0</b>        | <b>-1'450</b> |    | <b>1'603</b>     |
| <b>Financial assets</b> | <b>1'930'763</b> | <b>0</b> | <b>-340'386</b> | <b>0</b>      |    | <b>1'590'377</b> |
| <b>Fixed assets</b>     | <b>1'933'816</b> | <b>0</b> | <b>-340'386</b> | <b>-1'450</b> |    | <b>1'591'980</b> |

Accruals / divestitures are only reported net

|                         | 01.01.22         | Accruals       | Divestiture | Depreciations | %  | 31.12.22         |
|-------------------------|------------------|----------------|-------------|---------------|----|------------------|
| Operating equipment     | 1'101            | 0              | 0           | -550          | 50 | 551              |
| IT, technical equipment | 5'002            | 0              | 0           | -2'500        | 50 | 2'502            |
| <b>Tangible assets</b>  | <b>6'103</b>     | <b>0</b>       | <b>0</b>    | <b>-3'050</b> |    | <b>3'053</b>     |
| <b>Financial assets</b> | <b>1'681'508</b> | <b>249'255</b> | <b>0</b>    | <b>0</b>      |    | <b>1'930'763</b> |
| <b>Fixed assets</b>     | <b>1'687'611</b> | <b>249'255</b> | <b>0</b>    | <b>-3'050</b> |    | <b>1'933'816</b> |